Swiss Re (SR9A) Q2 2026 Earnings Report

The call presented a predominantly positive operational and financial picture: strong H1 net income (USD 2.8B), high ROE (23%), robust P&C combined ratio (76.7%), solid Life & Health Re results, healthy investment returns (4.0% ROI) and a very strong capital position (SST ~264%). Management also announced an increased cost-reduction target and continued active capital return (buyback). Offsetting risks include notable declines in new business CSM across segments, pricing pressure in specific lines (non-proportional property, parts of Specialty, Corporate rates), rising P&C expense ratio, and questions about the sustainability of large short-tail reserve releases. Overall, the positives (underwriting results, capital, investments, cost discipline) materially outweigh the headwinds related to new-business profitability and selective pricing pressure, but the latter warrant monitoring going into 2027.

Management reiterated a full‑year net income target of USD 4.5bn (H1 net income USD 2.8bn, >60% of target) and highlighted strong H1 metrics — group ROE 23% — while setting specific business targets and near‑term expectations: Life & Health H1 net income just over USD 1.0bn with a 2026 net income target of USD 1.7bn, an insurance service result of USD 1.2bn and a CSM release of USD 758m (annualized ~9%); P&C Re H1 insurance service result USD 1.8bn, combined ratio 76.7% (full‑year target <85%), new business CSM USD 1.6bn (vs USD 2.2bn prior) and USD 6–7bn of treaty renewals to end‑June; Corporate Solutions H1 combined ratio 86.1%, insurance service result USD 578m, CSM release ~USD 400m and new business CSM USD 201m (vs USD 262m prior); midyear renewals showed 11% volume growth and year‑to‑date premium volume +0.5% with nominal pricing broadly flat (casualty mid‑single‑digit increases, non‑prop property down high single digits), year‑to‑date loss assumptions +4.4% (explaining a ~4.6% risk‑adjusted price decline), investment ROI 4.0% with recurring income USD 2bn, estimated group SST 264% (up 14pp since Jan, ~5pp temporary benefit), ~60% of a USD 1.5bn buyback executed, an increased operating cost‑saving target of USD 500m by 2028 (run‑rate, reflected in FY2029), and management expects mid‑triple‑digit reserve releases to help offset renewal headwinds.